VPS35 and Parkinson disease: The other challenges will be to overcome in the translational therapeutic pipeline, including biomarker development, clinical trial strategies, and understanding the potential utility of VPS35 as therapeutic target in different PD backgrounds (sporadic and genetic PD cases).